Bücher veröffentlicht von Pharmagellan, LLC

If you work in or around biotech, you're supposed to understand clinical trial results. But what if you're not an expert in study design or biostatistics? You may feel out of your comfort zone when faced with a journal article, press release, or investor presentation. The Pharmagellan Guide to Analyzing Biotech Clinical Trials is a comprehensive primer to help non-experts evaluate clinical studies of new therapies.Structured roadmap for assessing the main components of a planned or completed biotech trial.Clear explanations of the most common concepts and terms in biotech clinical studies, illustrated with over 100 real-world examples.Deep dives on essential topics like p values, sample size calculations, and Kaplan-Meier curves, written in plain English for non-statisticians.Pointers for interpreting positive and negative study results, understanding common figures and tables, and identifying red flags in press releases. If you're a biotech executive, investor, advisor, or entrepreneur - or aspire to be one - this handbook will give you the foundation you need to analyze planned and completed clinical trials with more confidence.

If you're a biotech executive, investor, deal maker, entrepreneur, or adviser-or aspire to be one-then you need to know how to build and analyze forecasts and valuation models of R&D-stage drugs.THE PHARMAGELLAN GUIDE TO BIOTECH FORECASTING AND VALUATION is a comprehensive, thoroughly referenced handbook to creating and interpreting financial models for early-stage biopharma assets and companies.• Vetted benchmarks for key drivers of income, expenses, and valuation.• Proprietary analyses by Pharmagellan's experienced consulting team.• More than 150 current references from peer-reviewed research, industry white papers, and SEC filings.Whether you're making investment decisions, pitching to potential partners or funders, or assessing your own R&D program, this is the one-stop guide you need by your side.